SCHEMBL2008767

SCHEMBL2008767

COC(=O)C1[C@H]2CN(c3ccc(C(=O)NC4C5CC6CC(C5)CC4C6)c(SC)n3)C[C@@H]12

nearest known ligand 0.82

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 15/20 0.82
PDE4A P27815 1/20 0.58
HSD17B3 P37058 1/20 0.58
PDE4B Q07343 1/20 0.58
PDE4C Q08493 1/20 0.58
PDE4D Q08499 1/20 0.58
SIGMAR1 Q99720 1/20 0.58
IDH1 O75874 7/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12571564 1.00 HSD11B1 (0.82) HSD11B1PDE4AHSD17B3PDE4BPDE4C
SCHEMBL4104063 0.90 HSD11B1 (1.00) HSD11B1PDE4AHSD17B3PDE4BPDE4C
SCHEMBL3982044 0.90 HSD11B1 (1.00) HSD11B1PDE4AHSD17B3PDE4BPDE4C
SCHEMBL2005340 0.90 HSD11B1 (1.00) HSD11B1PDE4AHSD17B3PDE4BPDE4C
SCHEMBL3245326 0.90 HSD11B1 (1.00) HSD11B1PDE4AHSD17B3PDE4BPDE4C
SCHEMBL13600344 0.90 HSD11B1 (0.83) HSD11B1PDE4AHSD17B3PDE4BPDE4C
SCHEMBL2010231 0.90 HSD11B1 (0.83) HSD11B1PDE4AHSD17B3PDE4BPDE4C
SCHEMBL12571575 0.90 HSD11B1 (0.83) HSD11B1PDE4AHSD17B3PDE4BPDE4C
SCHEMBL3247089 0.85 HSD11B1 (0.77) HSD11B1PDE4AHSD17B3PDE4BPDE4C
SCHEMBL1968245 0.80 HSD11B1 (0.81) HSD11B1PDE4AHSD17B3PDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964618-B2 2-[(3R)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid, for example; compounds possess human 11- beta-hydroxysteroid dehydrogenase type1 enzyme (11 beta HSD1) inhibitory activity and accordingly have value in treatment of disease states including metabolic syndrome ASTRAZENECA AB (SE) 2011-06-21 US disclosed